FDA’s CDER Updates the Purple Book

February 24, 2017

On Tuesday, February 21st, the FDA’s Center for Drug Evaluation and Research (CDER) announced the availability of an updated version of the Purple Book.

What is the Purple Book?

“The ‘Purple Book’ lists biological products, including any biosimilar and interchangeable biological products, licensed by FDA under the Public Health Service Act (the PHS Act).”  The FDA developed these lists to serve as a resource to help users find out if the Agency has determined a biological product to be biosimilar to or interchangeable with a reference biological product.

There are separate lists for biological products regulated by CDER and those regulated by the Center for Biologics Evaluation and Research (CBER).

What information does the Purple Book include?

For products licensed under section 351(a) of the PHS Act, the Purple Book lists provide the following information:

  • Date the biological product was licensed by FDA.
  • Whether a biological product licensed under section 351(k) of the PHS Act has been determined to be biosimilar to or interchangeable with an already-licensed FDA biological product.
  • Whether FDA evaluated the biological product for reference product exclusivity under section 351(k)(7) of the PHS Act.

However, FDA states that “the list will not identify periods of orphan exclusivity and their expiration dates for biological products as those dates are available at the searchable database for Orphan Designated and/or Approved Products.”

What is a reference product, biosimilar, and interchangeable product?

Section 351(i)(4) of the PHS Act states that “a ‘reference product’ is the single biological product licensed by FDA under section 351(a) of the PHS Act against which a proposed biological product is evaluated in an application submitted under section 351(k).”

Biosimilar or biosimilarity means that, aside from minor differences in clinically inactive components, the biological product in question is extremely similar to the reference product.  Additionally, for a product to be considered biosimilar there must be no “clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency of the product.” (Section 351(i)(2) of the PHS Act)

“An ‘interchangeable’ biological product is a product that has been shown to be biosimilar to the reference product, and can be expected to produce the same clinical result as the reference product in any given patient.”  Furthermore, the risks of using the biological product must not be greater than the risks of using the reference product.

Updating the Purple Book

As resources permit, FDA states that the Purple Book will be updated as new biological products are licensed by FDA under section 351(a) or 351(k) of the PHS Act, and/or as it “makes a determination regarding date of first licensure for a biological product licensed under section 351(a) of the PHS Act.”

Earlier this week, the Agency announced the release of the latest version of CDER’s list, which was updated on February 16, 2017.  The latest version of CBER’s list was updated on December 20, 2016.

The Weinberg Group has a 35-year track record of helping our clients achieve successful interactions with the FDA and we have the experience you need to do exactly that.  Contact us today to learn more about our services and how we can help you develop and submit a successful application.

[pardot-form id="3339" title="New Standard Post Form"]


May 18, 2022

FDA Releases Draft Guidance for Industry on Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies

The FDA’s Office of Clinical Pharmacology within the Office of Translational Sciences released a new draft guidance document that, for the first time, clearly addresses the FDA’s recommendations and...

Read the Full Article
Regulatory Sciences

September 16, 2021

Have an FDA Submission on Your 2021 To-Do List?

At the start of every year, we all have these grand plans of everything we plan to accomplish. It is a fresh start to really get stuff done and we have a full 12 months to do it all. However,...

Read the Full Article
FDA North America

August 22, 2022

FDA Publishes Responses to Good Clinical Practice Inquiries

FDA Publishes Responses to Good Clinical Practice Inquiries: FDA oversees clinical trials to ensure they are designed, conducted, analyzed and reported according to federal law and FDA’s regulations....

Read the Full Article